Results 301 to 310 of about 2,230,930 (359)

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Epigenetic control of antigen presentation failure in osteosarcoma: from single-cell chromatin maps to therapeutic strategies. [PDF]

Front Immunol
He Y, Wu H.
europepmc   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

A comprehensive survey of genome language models in bioinformatics. [PDF]

Brief Bioinform
Shu L, Tang J, Guan X, Zhang D.
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

MdGATA15 regulates MdANR to promote the synthesis of procyanidin and enhance the sunburn resistance of apple fruit

Juanjuan Fu, Yifeng Feng, Yajin Zheng, Yuanwen Zhong, Xianglu Li, Li Liu, Zhengyang Zhao   +6 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Transposon invasion of primate genomes shaped human inflammatory enhancers and susceptibility to inflammatory diseases. [PDF]

Nat Commun
Ye M, Rotival M, Amigorena S, Zueva E.
europepmc   +1 more source

SEA version 4.0: a major expansion and update of the Super-Enhancer Archive. [PDF]

Nucleic Acids Res
Shi B, Zhao J, Li Y, Zhang C, Deng L, Ji C, Wang H, Zhai R, Feng T, Zhang Y, Gu Y.   +10 more
europepmc   +1 more source

TLX1 translocation variants and enhancer hijacking influence clinical outcome in T-cell acute lymphoblastic leukemia. [PDF]

Hemasphere
Balducci E, Steimlé T, Cieslak A, Charbonnier G, Pinton A, Simonin M, Smith C, Louis V, Féroul M, Delafoy M, Kaltenbach S, Bidet A, Grange B, Rigollet L, Villarese P, Touzart A, Dombret H, Baruchel A, Boissel N, Asnafi V.   +19 more
europepmc   +1 more source